Cancer combo trial halted early: did the STING agonist fall short?
Disease control
Terminated
This study tested whether adding an experimental drug called IMSA101 to a combination of targeted radiation (PULSAR) and standard immunotherapy could better control advanced lung or kidney cancer that had spread to a few spots. Only 6 people enrolled before the trial was stopped …
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated May 02, 2026 18:44 UTC